CN103372138B - A kind of pharmaceutical composition containing Shengmai Yin active ingredient and preparation method thereof - Google Patents
A kind of pharmaceutical composition containing Shengmai Yin active ingredient and preparation method thereof Download PDFInfo
- Publication number
- CN103372138B CN103372138B CN201210123804.1A CN201210123804A CN103372138B CN 103372138 B CN103372138 B CN 103372138B CN 201210123804 A CN201210123804 A CN 201210123804A CN 103372138 B CN103372138 B CN 103372138B
- Authority
- CN
- China
- Prior art keywords
- fruit
- weight
- chinese magnoliavine
- parts
- total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 239000009877 shengmai Substances 0.000 title claims abstract description 23
- 239000004480 active ingredient Substances 0.000 title claims abstract description 17
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 96
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 94
- 239000000341 volatile oil Substances 0.000 claims abstract description 46
- 229920002472 Starch Polymers 0.000 claims abstract description 45
- 235000008434 ginseng Nutrition 0.000 claims abstract description 45
- 235000019698 starch Nutrition 0.000 claims abstract description 45
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 44
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 44
- 229930182490 saponin Natural products 0.000 claims abstract description 38
- 150000007949 saponins Chemical class 0.000 claims abstract description 38
- 235000017709 saponins Nutrition 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract 13
- 241000208340 Araliaceae Species 0.000 claims abstract 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 155
- 239000000284 extract Substances 0.000 claims description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- 239000000706 filtrate Substances 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 36
- 239000000463 material Substances 0.000 claims description 34
- 238000001914 filtration Methods 0.000 claims description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 239000011347 resin Substances 0.000 claims description 27
- 229920005989 resin Polymers 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 20
- 238000001556 precipitation Methods 0.000 claims description 18
- 235000002789 Panax ginseng Nutrition 0.000 claims description 17
- 238000010828 elution Methods 0.000 claims description 17
- 239000003480 eluent Substances 0.000 claims description 15
- 235000019640 taste Nutrition 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- 239000006210 lotion Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 6
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims 2
- 235000019441 ethanol Nutrition 0.000 description 54
- 244000248557 Ophiopogon japonicus Species 0.000 description 46
- 241000700159 Rattus Species 0.000 description 42
- 239000000243 solution Substances 0.000 description 38
- 240000004371 Panax ginseng Species 0.000 description 35
- 206010019280 Heart failures Diseases 0.000 description 27
- 230000000694 effects Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 210000004165 myocardium Anatomy 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 239000000835 fiber Substances 0.000 description 11
- 230000002107 myocardial effect Effects 0.000 description 11
- 210000000702 aorta abdominal Anatomy 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 241000700157 Rattus norvegicus Species 0.000 description 9
- -1 homoisoflavone class Chemical class 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000005457 optimization Methods 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 230000002861 ventricular Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 230000004217 heart function Effects 0.000 description 6
- 238000011552 rat model Methods 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 235000020985 whole grains Nutrition 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000256856 Vespidae Species 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000001435 haemodynamic effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229930013686 lignan Natural products 0.000 description 3
- 235000009408 lignans Nutrition 0.000 description 3
- 150000005692 lignans Chemical class 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000168250 Cyphophthalmi Species 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019345 Heat stroke Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229930195210 Ophiopogon Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001756 Polyvinyl chloride acetate Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000496 cardiotonic agent Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007773 growth pattern Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 244000139693 Arctostaphylos uva ursi Species 0.000 description 1
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 1
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001506371 Kadsura Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000736078 Schisandra sphenanthera Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 125000002298 terpene group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition containing Shengmai Yin active ingredient and preparation method thereof, said composition contains the Radix Ginseng Rubra total saponins of 10~80 parts by weight, the tuber of dwarf lilyturf total starches of 100~800 parts by weight, the fruit of Chinese magnoliavine lignanoid of 0.375~12 parts by weight, the fruit of Chinese magnoliavine total volatile oil of 0.2~1.6 parts by weight.
Description
Technical field：
The present invention relates to a kind of pharmaceutical composition, more particularly to a kind of pharmaceutical composition containing Shengmai Yin active ingredient and
Preparation method and use.
Background technology：
Shengmai Yin, is a kind of traditional Chinese medicine, is formulated and is：100 grams of ginseng, 200 grams of the tuber of dwarf lilyturf, 100 grams of the fruit of Chinese magnoliavine.
Ginseng sweet is put down in side, and Yiqi and vein recovery promotes the production of body fluid to quench thirst, and is revitalized vigour, is main ingredient.The tuber of dwarf lilyturf is sweet cold, and reinforcing stomach reg fluid clears away heart-fire
Relieving restlessness, moistens the lung and nourish yin, and is adjuvant.Fruit of Chinese magnoliavine acid temperature, QI invigorating of astringing the lung promotes the production of body fluid to quench thirst, strengthening exterior and reducing sweat, antitoxic heart-soothing and sedative.Three medicines are shared,
One, which mends one clear one, holds back, the work(for Yiqi and vein recovery, nourishing Yin and promoting production of body fluid are played altogether, moistening the lung and relieve the cough.
Shengmai Yin cures mainly warm disease heat impairing qi the moon, burnout shortness of breath lazyness speech, thirsty hidrosis feeble pulse；Or deficiency of both vital energy and Yin, Tianjin dehydration is died,
Palpitation, weak pulse abnormal sweating；Or chronic cough of deficiency lung, the few phlegm of dry cough or without phlegm, dry throat tongue is dry, and tongue is red and dry, deficient and thready pulse person.Doctor trained in Western medicine is examined
For heatstroke, samples febrile disease, Japanese Type-B encephalitis, infectious shock, chronic bronchitis, chronic pharyngitis
Use this medicine.
Ginseng contains ginsenoside in Shengmai Yin side, can cardiac stimulant gas, tonifying lung gas；The function of fruit of Chinese magnoliavine Bearberry Extract, can prevent
Vigour dissipates；The tuber of dwarf lilyturf contains sugared body, energy nourishing Yin and clearing heat, therefore Shengmai Yin can prevent heatstroke in summer, can also protect gas health.
Wherein, red ginseng (Radix ginseng Rubra) is ginseng (Panax ginseng C.A.Meyer) through artificial steaming
The drying root and rhizome made and obtained after drying.Sweet, slight bitter is warm-natured, returns spleen, lung, the heart channel of Hang-Shaoyin, and with reinforcing vital energy, multiple arteries and veins is consolidated
It is de-, the effect of nourishing qi to stop.The active ingredient of red ginseng is broadly divided into three classes, i.e. volatile oil, ginsenoside and polysaccharide.Wherein ginseng
Saponin(e is the primary bioactive components of red ginseng, in terms of its bioactivity is mainly manifested in following four：(1) there is cardiac stimulant to make
With blood vessel can be expanded, with the effect resisted myocardial ischemia；(2) there is antitumor action；(3) immunity of organisms can be improved,
Improve function of immune system；(4) Central nervous act as improve memory, antidepression is calm and ease pain and simultaneously can effectively change
The mobility of kind aging animal decline.
The tuber of dwarf lilyturf is Liliaceae Ophiopogon (Ophiopogon Ker Gawl) the plant tuber of dwarf lilyturf (Ophiopogon
Japonicus (Lf) Ker Gawl) dried root, be one of traditional Chinese medicine.Sweet, slight bitter.With nourishing Yin and promoting production of body fluid, moistening lung is clear
Effect of the heart.Clinically it is mainly used in the diseases such as consumption of body fluid caused by febrile disease, restlessness and thirst, dryness of the lung dry cough.Tuber of dwarf lilyturf main chemical compositions are steroidal
Saponin(e, polysaccharide, homoisoflavone class, amino acid etc..Wherein ophiopogonpolysaccharide is one of main component of the tuber of dwarf lilyturf.Ophiopogonpolysaccharide in recent years
Bioactivity research show, ophiopogonpolysaccharide tool multiple biological activities, be concentrated mainly on resist myocardial ischemia, hypoglycemic, resist oxygen lack
Ability, immunocompetence, antiallergic activity, to intestines and stomach action activity in terms of, body hypoxia-bearing can be increased；With the anti-rhythm of the heart
Not normal effect；Can be hypoglycemic, and the recovery of islet cells can be promoted；Raising immunologic function and nucleic acid synthetic ratio, promotion antibody,
Generation of complement, lysozyme etc. etc..
The fruit of Chinese magnoliavine is Magnoliaceae schisandra plant fruit of Chinese magnoliavine Schisandra chiensis (Turcz) Ball or Central China
Fruit of Chinese magnoliavine Schisandra sphenanthera Rehd Et Wils dry mature fruit, first recorded in《Sheng Nong's herbal classic》.
The former is distributed mainly on China northeast, the Inner Mongol and East China, is commonly called as " fructus schisandrae ", and the latter's main product is in Central China and southwest ground
All provinces on the south area and the Qinling Mountains, its effect is identical with fructus schisandrae, is commonly called as " kadsura longepedunculata ".The fruit of Chinese magnoliavine is warm-natured, sour, sweet.Energy
Restrain astringent or styptic treatment for spontaneous sweating, nourishing generate fluid, kidney calming.Declined for chronic cough and dyspnea of deficiency type, thirsty body fluid deficiency, seminal emission, spontaneous perspiration, night sweat, chronic diarrhea, nerve
The diseases such as weak, hepatitis.The fruit of Chinese magnoliavine mainly contains a variety of chemical compositions such as lignanoid, volatile oil, organic acid and polysaccharide.Contain in the fruit of Chinese magnoliavine
The a variety of lignans having are considered as topmost pharmacological component in the fruit of Chinese magnoliavine, except with reduction liver cell SGPT
Effect is outer also to have anti HIV-1 virus, anti-oxidant, protection central nervous system effect and stable effect.Fructus Schisandrae Chinensis volatile oil master
It is terpenoid to want composition, and based on sesquiterpenoids, with antitussive effect, central nervous system can be adjusted indirectly.To the five tastes
Sub- volatile oil carries out Pharmacological Activity Screening, shows that it has the former activator inhibitor activity of stronger antiplasmin.
At present, existing Shengmai San or Shengmai Yin product is ginseng, the tuber of dwarf lilyturf, the taste medicine of the fruit of Chinese magnoliavine three according to certain ratio
Prepared by the method decocted or remixed respectively after extraction altogether, for example：Ginseng, the tuber of dwarf lilyturf, Fructus Schisandrae Chinensis powder is broken into coarse powder, uses 65% second
Alcohol makees solvent, and dipping carries out diacolation after 24 hours, collect the liquid about 4500ml that filters, be concentrated under reduced pressure into about 250ml, let cool, add water
400ml dilutes, filtration, separately adds 60% syrup 300ml and appropriate preservative, and adjusts pH value to prescribed limit, and adjustment total amount is extremely
1000ml, is stirred evenly, and is stood, filtration, embedding, and sterilizing is produced.
But Chinese medicine compound prescription complicated component, often by several, ten several to tens kinds or more kind composition compositions, these compositions
In some undoubtedly played a key effect for treatment disease, and other compositions then unavoidable toxic side effect.Such as pulse invigorating injection
Liquid, its clinical adverse report is increasing.Such as the serious abdominal distension of shengmai injection cause, skin hypersensitivity erythema, anaphylaxis is stopped
Gram and low blood pressure, and heartbeat can be induced overrun, angina pectoris etc., though be a small number of cases, but it should drawing attention.
In addition, the preparation method that three taste medicines are remixed after extracting respectively in the prior art is also mainly according to conventional formulation people
100 grams of ginseng, 200 grams of the tuber of dwarf lilyturf, the dose design that 100 grams of the fruit of Chinese magnoliavine, after each medicinal material carries out extraction processing with modernism
To product still continue to use said ratio mixed whether rationally, it is unknown, for obtain it is more efficient it is rational extract processing
The proportioning of product afterwards, the present invention has carried out technology screening.By screening, present invention finds a kind of different from prior art
Proportioning, while medicinal material consumption is reduced, obtains the effect same with prior art.
The present invention extracts three taste the effective elements of the medicines respectively by prolonged checking research repeatedly, selection：The total soap of red ginseng
Glycosides, tuber of dwarf lilyturf total starches, fruit of Chinese magnoliavine lignanoid and Fructus Schisandrae Chinensis volatile oil, these four active ingredients are mixed according to certain ratio
Close, and the proportioning between each active ingredient is optimized, finally give the pharmaceutical composition of the present invention.Present invention additionally comprises this
The preparation method and its preparation and purposes of pharmaceutical composition.
The content of the invention：
It is an advantage of the invention to provide one kind comprising Radix Ginseng Rubra total saponins, tuber of dwarf lilyturf total starches, fruit of Chinese magnoliavine lignanoid and
The pharmaceutical composition of fruit of Chinese magnoliavine total volatile oil.It is a further object of the invention to provide the preparation side of aforementioned pharmaceutical compositions
Method.A further object of the present invention is that there is provided the preparation comprising aforementioned pharmaceutical compositions.Final object of the present invention exists
In there is provided the purposes of aforementioned pharmaceutical compositions.
The present invention provides a kind of pharmaceutical composition containing Shengmai Yin active ingredient, and said composition contains 10~80 parts by weight
Radix Ginseng Rubra total saponins, the tuber of dwarf lilyturf total starches of 100~800 parts by weight, the fruit of Chinese magnoliavine lignanoid of 0.375~12 parts by weight, 0.2~
The fruit of Chinese magnoliavine total volatile oil of 1.6 parts by weight.
It is preferred that, said composition contains：The parts by weight of Radix Ginseng Rubra total saponins 20~80, the parts by weight of tuber of dwarf lilyturf total starches 200~800,
The parts by weight of fruit of Chinese magnoliavine lignanoid 0.375~1.5, the parts by weight of fruit of Chinese magnoliavine total volatile oil 0.4~1.6.
Particularly preferred, said composition contains：The parts by weight of Radix Ginseng Rubra total saponins 80, the parts by weight of tuber of dwarf lilyturf total starches 800, the fruit of Chinese magnoliavine
The parts by weight of lignanoid 1.5, the parts by weight of fruit of Chinese magnoliavine total volatile oil 1.6.
Or
The parts by weight of Radix Ginseng Rubra total saponins 40, the parts by weight of tuber of dwarf lilyturf total starches 400, the parts by weight of fruit of Chinese magnoliavine lignanoid 0.75, the fruit of Chinese magnoliavine
The parts by weight of total volatile oil 0.8.
Or
The parts by weight of Radix Ginseng Rubra total saponins 20, the parts by weight of tuber of dwarf lilyturf total starches 200, the parts by weight of fruit of Chinese magnoliavine lignanoid 0.375, the fruit of Chinese magnoliavine
The parts by weight of total volatile oil 0.4.
The pharmaceutical composition of the present invention, can also contain pharmaceutically acceptable carrier as needed.
The pharmaceutical composition of the present invention, is any one pharmaceutical dosage forms.
The pharmaceutical composition of the present invention, is the pharmaceutical preparation of gastrointestinal administration or parenteral administration.
The present invention also provides the preparation method of the pharmaceutical composition of the present invention, and such as by mixing Radix Ginseng Rubra total saponins, the tuber of dwarf lilyturf is total
It is prepared by polysaccharide, fruit of Chinese magnoliavine lignanoid, fruit of Chinese magnoliavine total volatile oil and pharmaceutically acceptable carrier.
The present invention also provides application of the pharmaceutical composition of the present invention on the medicine for preparing treatment chronic heart failure.
The pharmaceutical composition of the present invention, can be any medicament forms taken：Such as：Tablet, sugar coated tablet, film-coating
Tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, mouth containing agent, granule, electuary, pill, powder,
Paste, sublimed preparation, supensoid agent, pulvis, solution, injection, suppository, ointment, emplastrum, creme, spray, drops, patch.
The pharmaceutical dosage forms of the pharmaceutical composition, preferably unit dose of the present invention.
The pharmaceutical composition of the present invention, when medicament is made, the medicament of unit dose can the pharmaceutical activity containing the present invention
Material 0.1-1000mg, remaining is pharmaceutically acceptable carrier.Pharmaceutically acceptable carrier can be preparation by weight
The 0.01-99.99% of gross weight.
The composition of the present invention determines usage and dosage according to the situation of patient when in use, such as 1-3 times on the one.1-10
Piece etc..
It is preferred that, composition of the invention is oral formulations or injection.
Wherein, the oral formulations are in capsule, tablet, dripping pill, granule, condensed pill, oral liquid and mixture
It is a kind of.
Wherein, the one kind of the injection in parenteral solution, freeze drying powder injection and liquid drugs injection.
The pharmaceutical composition of the present invention, its preparation being administered orally can contain conventional excipient, such as adhesive, filling
Agent, diluent, tablet agent, lubricant, disintegrant, colouring agent, flavor enhancement and wetting agent, can be coated to tablet if necessary.
Applicable filler includes cellulose, mannitol, lactose and other similar fillers.Suitable disintegrant bag
Include starch, polyvinylpyrrolidone and starch derivatives, such as sodium starch glycollate.Suitable lubricant includes, for example firmly
Fatty acid magnesium.Suitable pharmaceutically acceptable wetting agent includes lauryl sodium sulfate.
The pharmaceutical composition of the present invention can be filled by mixing, and the conventional method such as tabletting prepares solid oral composition.
Carrying out mixing repeatedly can be such that active material is distributed in entirely using in those compositions of a large amount of fillers.
The form of oral liquid for example can be aqueous or oily suspensions, solution, emulsion, syrup or elixir,
Or can be a kind of dry products that can be compounded before use with water or other suitable carriers.This liquid preparation can contain
Conventional additive, such as suspending agent, such as sorbierite, syrup, methylcellulose, gelatin, hydroxyethyl cellulose, carboxymethyl are fine
Dimension element, aluminium stearate gel or hydrogenated edible fats, emulsifying agent, such as lecithin, anhydro sorbitol monooleate or Arab
Glue；Non-aqueous carrier (they can include edible oil), such as apricot kernel oil, fractionated coconut oil, the oily ester of the ester of such as glycerine,
Propane diols or ethanol；Preservative, such as para hydroxybenzene methyl esters or propylparaben or sorbic acid, and if desired,
Conventional flavouring agent or colouring agent can be contained.
For injection, the fluid unit dosage form of preparation contains the active material and sterile carrier of the present invention.According to carrier
And concentration, this compound can be suspended or be dissolved.The preparation of solution is dissolved in a kind of load typically by by active material
In body, sterilization is filtered before a kind of suitable bottle or ampoule is loaded into, is then sealed.For example a kind of local anaesthesia of auxiliary material
Agent, preservative and buffer can also be dissolved in this carrier., can be after bottle be loaded by this in order to improve its stability
Composition frost is planted, and under vacuo removes water.
The pharmaceutical composition of the present invention, suitable pharmaceutically acceptable load is optionally added when being prepared into medicament
Body, the pharmaceutically acceptable carrier is selected from：Mannitol, sorbierite, sodium pyrosulfite, sodium hydrogensulfite, sodium thiosulfate, salt
Sour cysteine, TGA, methionine, injection Vitamin B_6 DTA disodiums, Ethylenediaminetetraacetic Acid Calcium Salt, carbonate, the acetic acid of monovalence alkali metal
Salt, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acid, sodium chloride, potassium chloride, sodium lactate, xylitol, wheat
Bud sugar, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and its
Derivative, alginates, gelatin, polyvinylpyrrolidone, glycerine, POLYSORBATE 80, agar, calcium carbonate, calcium bicarbonate, surface-active
Agent, polyethylene glycol, cyclodextrin, beta-schardinger dextrin, phospholipid material, kaolin, talcum powder, calcium stearate, magnesium stearate etc..
Radix Ginseng Rubra total saponins of the present invention, tuber of dwarf lilyturf total starches, fruit of Chinese magnoliavine lignanoid, fruit of Chinese magnoliavine total volatile oil can basis
Prepared by prior art, can also be prepared by the following method：
The preparation of red ginseng saponin component：
Red ginseng is extracted 1~5 time with 20~95% ethanol, merges extract solution, and extract solution reclaims ethanol to without alcohol taste, added water dilute
Release to medicinal material than 1: 2~1: 10, filter to get filtrate, filtrate is through macroporous resin column chromatography, successively with water, 0.1~10%NaOH (4-
5BV), 20~95% ethanol elution, collects 50~80% ethanol eluates and is concentrated to dryness, produce.
The preparation of ophiopogonpolysaccharide component：
The tuber of dwarf lilyturf is extracted 1~5 time with water, is merged extract solution, is concentrated into medicinal material than 1: 2~1: 10, filters to get filtrate, filtrate warp
Macroporous resin column chromatography, is washed with water (2-4BV), collects efflux and water lotion, be concentrated into density be respectively 1.05-1.10,
1.13-1.17, by alcohol precipitation twice (60~80%, 65~85%), collects precipitation, drying is produced.
Fruit of Chinese magnoliavine lignanoid and the preparation of volatile oil compositions：
Fruit of Chinese magnoliavine coarse powder obtains Fructus Schisandrae Chinensis volatile oil by supercritical extract.
The residue that supercritical extract is obtained is extracted 1~5 time with 20~95% ethanol, merges extract solution, and filtering, filtrate is closed
And, medicinal material is concentrated into than 1: 2~1: 10, is filtered, filtrate is through macroporous resin column chromatography, successively with water, 30~95% ethanol elutions,
Eluent is concentrated to dryness, and is produced.
It is preferred that, Radix Ginseng Rubra total saponins of the present invention, tuber of dwarf lilyturf total starches, fruit of Chinese magnoliavine lignanoid, fruit of Chinese magnoliavine total volatile oil
It is prepared by the following method：
The preparation of red ginseng saponin component：
Red ginseng is extracted 2 times with 80% ethanol, merges extract solution, and extract solution reclaims ethanol to without alcohol taste, is diluted with water to medicine
Material ratio is 1: 5, and filtering, filtrate uses water, 0.1%NaOH (4~5BV), 80% ethanol elution successively through macroreticular resin, collects elution
Liquid, is concentrated to dryness, and obtains Radix Ginseng Rubra total saponins.
The preparation of ophiopogonpolysaccharide component：
The tuber of dwarf lilyturf is extracted 2 times with water, is merged extract solution, is recycled to medicinal material than 1: 5, is filtered, and filtrate washes (2 through macroreticular resin
~4BV), collect efflux and water lotion, it is respectively 1.05-1.10,1.13-1.17 to be concentrated into density, twice alcohol precipitation (80%,
85%) precipitation, is collected, drying obtains tuber of dwarf lilyturf total starches.
Fruit of Chinese magnoliavine lignanoid and the preparation of volatile oil compositions：
Fruit of Chinese magnoliavine coarse powder obtains Fructus Schisandrae Chinensis volatile oil by supercritical extract.
The residue that supercritical extract is obtained is extracted 2 times with 80% ethanol, merges extract solution, and extract solution filtering, filtrate merges,
It is 1: 5 to be concentrated into medicinal material ratio, and filtering, filtrate uses water, 95% ethanol elution successively through macroreticular resin, and eluent is concentrated to dryness, obtained
Fruit of Chinese magnoliavine lignanoid.
The proportioning of the present invention is obtained by screening, and screening process is as follows：
Test a Shengmai Yin active ingredient compatibility Optimal Experimental
1 experiment material
1.1 experimental animal
SD rats (200 ± 5g, credit number：SCXk (Tianjin) 2009-0001), it is purchased from the red experimental animal in Tianjin mountains and rivers limited
Company.
1.2 experimental drug
Shengmai Yin active ingredient：Total saposins, total lignan, total starches, total volatile oil (preparation of the method for embodiment 6)
Positive control drug：SHENGMAI YIN KOUFUYE (Jilin shows the scientific and technological pharmaceutical Co. Ltd in peak)
1.3 laboratory apparatus
Color ultrasound image diagnostic equipment (VIVID 7)；Eight lead physiograph；Ware electronic balance (Shanghai in JA1003 types
Jing Ke companies)；CKF-06A types electric oven (Shuande mayor contains Electrical Appliances Co., Ltd)；202-AUBS type electrically heated drying cabinets (Tianjin
North China laboratory apparatus Co., Ltd)；- 20 DEG C of refrigerators of BCD-256KF Type Bs (Qingdao HaiEr Co., Ltd)；OLYMPUS U-
CMAD3 types light microscope (Japanese OLYMPUS companies production)；OLYMPUS C5060-ADU type light microscopics camera (Japan
OLYMPUS companies produce)；820ROTARYMICROTOME types paraffin slicing machine (American Optical companies of the U.S.).
1.4 experiment reagent
37.0%~40.0% formalin (Tianjin, which is won, reaches your dilute chemical reagent factory)；Absolute ethyl alcohol (Tianjin wind ship
Chemical reagent Science and Technology Ltd.)；95% ethanol (Tianjin Fengchuan Chemical Reagent Science ＆ Technology Co., Ltd.)；Dimethylbenzene (analysis is pure,
Tianjin north day medical chemistry chemical reagent work)；Paraffin (58~60 DEG C of fusing point) (Chinese Shanghai Yi Yang Instrument Ltd.)；Efficiently cut
Piece paraffin (48~50 DEG C of fusing point) (Shanghai Hua Yong paraffin Co., Ltd)；Masson kits (science and technology is built up in Nanjing company).
2 experimental methods
2.1 abdominal aorta constriction methods replicate heart failure rat model
Reference literature[1-2]Method simultaneously replicates heart failure rat model according to this laboratory early stage preliminary experiment, and brief step is as follows：
Rat 10% chloraldurate intraperitoneal injection of anesthesia, xiphoid-process median incision of lower abdomen, layering opening abdominal cavity, in left and right renal artery branch
Between passivity dissociate abdominal aorta, be placed in No. 7 syringe needles are parallel on abdominal aorta, with No. 4 operation silk threads by abdominal aorta
Together ligature, then slowly withdraw from syringe with syringe, close abdomen, layering suture, make the rat aorta narrowed diameter be
0.7mm.Sham-operation group is opened operation silk thread after abdomen through abdominal aorta, in addition to not constriction abdominal aorta, other operations and operation
Group is identical.
2.2 experiment packets and medication
Gentamicin is continuously injected intraperitoneally 3 days in Post operation, starts administration after mouse is in stable condition.Setup Experiments sham-operation
Group, model group and 8 groups of the different component compatibility obtained by uniform design Software for Design.The equal gastric infusion of each group animal,
0.5ml/100g, successive administration 6 weeks.
According to document[3]The LD50 of Shengmai Yin be 69.4g/kg (rat), with its 1/10 for pharmacodynamic experiment high dose,
Four components of Shengmai Yin are respectively in 1/10-1/80LD50 dosage ranges[4], design the level of 4 factor 8 by Uniform ity Design Method real
Test, drug ratio experimental design such as following table.
[the U of table 18(84)] uniform designs table
The each component compatibility of table 2 is grouped situation
3. Testing index
3.1 detection heart functions
Influence with Color doppler ultrasound each component to heart failure in rats[5-6].It is administered after 6 weeks, each group
Rat yellow Jackets intraperitoneal anesthesia, is cut with Cyphophthalmi and carefully cuts off rat thorax abdomen hair, is surveyed on long axis view of the left heart
Measure and record rat heart indices：Left Ventricular Ejection Fraction (EF)=SV/LVEDV × 100%；LVED
(LVDd), left room end systolic diameter (LVDs)；Left room interventricular septum thickness at enddiastole (LVSd), left room end-systole interventricular septum
Thickness (LVSs)；Wall thickness (LVPWs) after left room posterior wall thickness at end-diastole (LVPWd), left room end-systole；Left room short axle contracting
Short rate (FS)=(LVDd-LVDs)/LVDd × 100%；Left ventricular end diastolic volume (LVEDV), left ventricular end-systolic volume
(LVESV)；Cardiac output of often fighting (SV).All data are measured 3 times, record its average value.
3.2 detection haemodynamics
Influence of the physiograph detection each component to Heart Failure Wistar Rats haemodynamics is led with eight.It is administered after 6 weeks, model
Heparin is full of in rat yellow Jackets intraperitoneal anesthesia, conduit, right common carotid artery retrograde catheterization is to left ventricle, another termination eight
Physiograph is led, is obtained after record analysis under left ventricular end diastolic presssure (LVEDP), left ventricular systolic pressure (LVSP), left indoor pressure rising
Maximum rate (± dp/dt), heart rate (HR) drop[7-8]。
4 experimental results
4.1 Heart Failure Wistar Rats models are verified
After abdominal aorta constriction 6 weeks, the influence with Color doppler ultrasound each component to heart failure in rats.
Compared with sham-operation group, model group heart function is decreased obviously, and is shown as：EF, FS are reduced；IVSd、IVSs、LVDd、LVDs、
LVPWd, LVEDV, LVESV, SV are raised, and the results are shown in Table 3.Leading physiograph with eight detects each component to Heart Failure Wistar Rats blood
The influence of hydromechanics.Compared with sham-operation group, model group LVEDP is significantly raised, LVSP, ± dp/dt are substantially reduced, as a result
It is shown in Table 4.As a result heart failure rat model stability is pointed out, can be used for experiment.
The influence (n=6) of the heart failure in rats of table 3
The influence (n=3) of the Heart Failure Wistar Rats haemodynamics of table 4
Each experimental group different component of 4.2 Shengmai Yins is with the influence for comparing heart failure in rats
Abdominal aorta constriction simultaneously gives Shengmai Yin experimental group different component of the present invention after 6 weeks simultaneously, and each experimental group can not
Improve heart function with degree.Each group measurement result is shown in Fig. 1, table 5.
Influence (n=6) of each experimental group of table 5 to heart failure in rats
It is as a result as follows with uniform design software analysis EF values：
Regression equation Y1：
Analysis of variance table
Multiple correlation coefficient=0.999999246 residual standard deviation=1.9880E-02
5 brief summaries
5.1 Doppler color ultrasounds check that binding of pathological analysis result shows, this research is answered using abdominal aorta constriction method
The heart failure rat model stability of system is reliable.
5.2 using EF as main inspection target, and Shengmai Yin different component compatibility of the present invention is carried out using uniform design software
Optimization analysis, obtains optimum optimization compatibility and is combined as：Total saposins 80mg/kg, total starches 800mg/kg, total lignan 1.5mg/kg,
Total volatile oil 1.6mg/kg.
Test the optimal compatibility confirmatory experiment of two Shengmai Yin active ingredients
1 experiment material
With experiment one.
2 experimental methods
2.1 abdominal aorta constriction methods replicate heart failure rat model
Method is with experiment one.
2.2 experiment packets and medication
Gentamicin is continuously injected intraperitoneally 3 days in Post operation, starts administration after mouse is in stable condition.Setup Experiments sham-operation
Group, model group, high, medium and low group of active compound (comparison medicine) and the high, medium and low dosage group for optimizing optimal compatibility.Each group animal is equal
Gastric infusion, 0.5ml/100g, successive administration 8 weeks.
The each component compatibility of table 6 packet situation (mg/kg)
Note：Each component ratio is under clinical equivalent dosage：Total saposins 23.76mg/kg, total starches 183.6mg/kg, hammer butt
Fat element 3.24mg/kg, total volatile oil 0.41mg/kg.Clinical equivalent dosage is to press active compound (i.e. comparison medicine SHENGMAI YIN KOUFUYE)
It is converted into what is come according to paste-forming rate of the crude drug amount with reference to each component is taken day.
3. Testing index
3.1 detection heart functions
Influence with Color doppler ultrasound each group medicine to heart failure in rats[5-6].It is administered after 8 weeks, each group
Rat yellow Jackets intraperitoneal anesthesia, is cut with Cyphophthalmi and carefully cuts off rat thorax abdomen hair, is surveyed on long axis view of the left heart
Measure and record rat heart indices：LVED (LVDd), left room end systolic diameter (LVDs)；Relax left room
Open latter stage IVSTd (LVSd), left room end-systole IVSTd (LVSs)；Left room posterior wall thickness at end-diastole
(LVPWd), wall thickness (LVPWs) after left room end-systole；Left Ventricular Ejection Fraction (EF)=SV/LVEDV × 100%；Left room is short
Axle LVFS (FS)=(LVDd-LVDs)/LVDd × 100%；Left ventricular end diastolic volume (LVEDV), left room end-systole hold
Product (LVESV)；Cardiac output of often fighting (SV).All data are measured 3 times, record its average value.
3.2 observation myocardial histopathology forms
Each group cardiac muscular tissue is taken at random, is routinely operated, tissue is through FFPE, section, HE dyeing, the light Microscopic observation heart
The change of muscular tissue[9]。
The change of 3.3 observation myocardial collagens
Every rat chooses 3 histotomies and carries out Masson dyeing, and system is analyzed using the medical images of Image-Pro 6.1
System, measurement myocardial collagen fraction by volume (CVF) and the ratio between collagen volume fraction and Lumen Area (PVCA).Calculating side
Method：CVF=myocardial collagens area/survey area of collagen/tube chamber face around field area × 100%, PVCA=petty action vessel lumen
Product × 100%, every myocardial slices sample takes 4 perimetries at random, takes its average value[10]。
4 experimental results
4.1 each group rat body weight growth patterns
Rat body weight record display：Compared with sham-operation group, model group rats body weight increase is slow；Compared with model group,
Other each group rat body weights increase very fast, and optimization middle dose group rat body weight increases particularly evident, and being compared with model group has significantly
Sex differernce (is shown in Table 7, Fig. 3).
The each group rat body weight increment of table 7
#Compared P ＜ 0.05 with model group；##Compared P ＜ 0.01 with model group；
Influence of the 4.2 each group medicines to heart failure in rats
After each group rat medication 8 weeks, the influence with Color doppler ultrasound each group medicine to heart failure in rats
(see Fig. 4, table 8).Compared with sham-operation group, model group rats EF is significantly reduced (P ＜ 0.01)；Compared with model group, active compound height,
In, low dose group can raise EF (P ＜ 0.01, P ＜ 0.05, P ＜ 0.05)；Compared with model group, optimize high, medium and low dosage
Group can raise EF (P ＜ 0.01, P ＜ 0.01, P ＜ 0.05)；In addition, each group medicine is to heart failure in rats other indexs
Influence has similar trend.As a result point out：Compared with active compound group, the effect that optimization group improves heart failure in rats becomes apparent from.
Influence of the 4.3 each group medicines to Heart Failure Wistar Rats myocardial histopathology form
It is seen from fig 5 that sham-operation group cardiac muscle fibre marshalling, nucleus is centrally located, connected between cardiac muscle fibre
Relative close；Model group cardiac muscle fibre thickening, arrangement disorder, gap are broadening, and nucleus contaminates greatly and deeply, area of section increase；With
Model group is compared, and active compound each group rat heart muscle fiber alignment is relatively neat, and nucleus is centrally located, connects relative between cardiac muscle fibre
Closely；Compared with model group, optimization each group rat heart muscle fiber row is neat, nucleus is smaller, is completely embedded between cardiac muscle fibre；Knot
Fruit is pointed out, and is compared with active compound each group, and optimization each group rat heart muscle fiber alignment is more neat, is connected between cardiac muscle fibre closer.4.4
Influence of each group medicine to Heart Failure Wistar Rats myocardial collagen
As seen from Figure 6, myocardial collagen fiber is dyed to blueness, is distributed in cardiac muscle, is mainly gathered in around blood vessel.
There are a small amount of collagenous fibres between rats in sham-operated group cardiac muscle cell, around blood vessel；Around model group rats cardiac interstitium and blood vessel
Collagenous fibres showed increased, and arrangement disorder；Compared with model group, active compound each group rat heart muscle interstitial and perivascular collagen are fine
Dimension is less, arranges more neat；Compared with model group, have a small amount of collagen fine around optimization each group rat heart muscle interstitial and blood vessel
Dimension, marshalling.As a result point out, compared with active compound each group, optimization each group rat heart muscle interstitial and perivascular collagen fiber contain
Amount is lower, arranges more neat.
5 conclusions
Confirmatory experiment result shows that it is big that Shengmai Yin active compound (i.e. comparison medicine) can improve experimental heart failure to a certain extent
The cardiac function of mouse, prescription of the present invention is respectively provided with substantially after constituent optimization to Heart Failure Wistar Rats cardiac function and Pathological structure
Improved effect, its effect and original prescription are equivalent.
Bibliography：
[1] Zhang Dongying, Luo Yuhui, Yang Hui, wait coronary artery ligations and chronic heart failure caused by abdominal aorta constriction big
Mouse model compares the Chinese microcirculations of [J], 2005,9 (3)：171-174.
[2] Hu Yongmei, Li Faqi, Luo Yuhui, wait the modelling of rats with abdominal aorta coarctation and clinical meaning [J] Chongqing
Medical university journal, 2004,29 (3)：322-324.
[3] Wang Yaoxian, He Mei give birth to animal acute morta-lity method estimate four kinds of Chinese patent drugs pharmacokinetic parameters [J] in into
Medicine, 1991,13 (5)：24-25.
[4] herbal pharmacology experimental methodology [M] Shanghai science tech publishing house .2006,38-39.
[5] Ma Xiaoyan, Wang Yi, Xu Qiang, wait the feasibility study [J] of color doppler ultrasound in assessment of heart function in rat days
Tianjin university of TCM journal .2007,26 (1)：25-28.
[6] Wang Weiting, Yu Bing, Zhao Kerui, wait the anti-heart of Heart Failure Wistar Rats CDFI features and astragalus injection
The effect of declining [J] Chinese herbal medicines, 2006,37：54-58.
[7] Zhang Shantang, Wang Qinmao, Chen Liming, wait Shenmai injections to the easypro contracting performance in the left room of rats with experimental heart failure
And plasma A ng II, ET and ANP Chinese combination of Chinese tradiational and Western medicine first aid magazines of influence [J], 2001,8 (1)：21-24.
[8] Ma Xiaobin, Wang Yanghui, Liu Jianxun, wait Shenqiyixin Granules to chronic heart failure rats haemodynamics
Influence [J] Chinese experimental pharmacology of traditional Chinese medical formulae magazines, 2007,13 (11)：27-29.
[9] foundation [J] Chengde of Xie Yaqin, Kang great Wei, Li Xiu China chronic heart failure myocardial fibrosis rat models
Medical college's journal, 2011,28 (1)：10-12.
[10] Cheng Jingsong, Zhao Yulan 2, willow is contained, and waits Candesartans to suppress chronic heart failure Rat Myocardial Fibrosis and reduce
Myocardial transformation grouth factor beta 1, connective tissue growth factor expression [J] Chinese Pharmaceutical Journals, 2009,44 (11)：832-835.
Brief description of the drawings：
The influence of Fig. 1 heart failure in rats
Fig. 2 is to seek optimal solution graph
Fig. 3 each group rat body weight growth patterns
Influence of Fig. 4 each groups medicine to heart failure in rats
Influence of Fig. 5 each groups medicine to Heart Failure Wistar Rats myocardial histopathology form
Influence of Fig. 6 each groups medicine to Heart Failure Wistar Rats myocardial collagen
Embodiment：
The present invention is further illustrated below by specific embodiment, following embodiments are to be used to illustrate rather than
Limitation of the present invention, claimed model is belonged to according to the simple modifications that the essence of the present invention is carried out to the present invention
Enclose.
Embodiment 1
Said composition contains：The parts by weight of Radix Ginseng Rubra total saponins 80, the parts by weight of tuber of dwarf lilyturf total starches 800, the weight of fruit of Chinese magnoliavine lignanoid 1.5
Measure part, the parts by weight of fruit of Chinese magnoliavine total volatile oil 1.6.
The parts by weight of starch 100
The parts by weight of microcrystalline cellulose 100
The parts by weight of magnesium stearate 10
By mixing, pelletize, dry, whole grain, tabletting, coating obtains coating tablet.
Embodiment 2
The parts by weight of Radix Ginseng Rubra total saponins 40, the parts by weight of tuber of dwarf lilyturf total starches 400, the parts by weight of fruit of Chinese magnoliavine lignanoid 0.75, the fruit of Chinese magnoliavine
The parts by weight of total volatile oil 0.8.
The parts by weight of starch 100
The parts by weight of microcrystalline cellulose 100
The parts by weight of magnesium stearate 10
By mixing, pelletize, dry, whole grain is encapsulated, produces.
Embodiment 3
The parts by weight of Radix Ginseng Rubra total saponins 20, the parts by weight of tuber of dwarf lilyturf total starches 200, the parts by weight of fruit of Chinese magnoliavine lignanoid 0.375, the fruit of Chinese magnoliavine
The parts by weight of total volatile oil 0.4.
The parts by weight of dextrin 50
The parts by weight of starch 100
The parts by weight of microcrystalline cellulose 100
The parts by weight of magnesium stearate 10
By mixing, pelletize, dry, whole grain, tabletting, coating obtains coating tablet.
Embodiment 4
The parts by weight of Radix Ginseng Rubra total saponins 20, the parts by weight of tuber of dwarf lilyturf total starches 200, the parts by weight of fruit of Chinese magnoliavine lignanoid 0.375, the fruit of Chinese magnoliavine
The parts by weight of total volatile oil 0.4.
The parts by weight of starch 100
The parts by weight of microcrystalline cellulose 100
The parts by weight of magnesium stearate 10
By mixing, pelletize, dry, whole grain is encapsulated, produces.
Embodiment 5
The parts by weight of Radix Ginseng Rubra total saponins 20, the parts by weight of tuber of dwarf lilyturf total starches 200, the parts by weight of fruit of Chinese magnoliavine lignanoid 0.375, the fruit of Chinese magnoliavine
The parts by weight of total volatile oil 0.4.
The parts by weight of lactose 100
The parts by weight of Catergen 0
The parts by weight of water for injection 200
By mixing, filter, sterilize, bottling is produced.
Embodiment 6
Active component Radix Ginseng Rubra total saponins in above example, tuber of dwarf lilyturf total starches, fruit of Chinese magnoliavine lignanoid, the fruit of Chinese magnoliavine is always volatilized
The preparation of oil：
(1) red ginseng, 80% ethanol is extracted 2 times, merges extract solution, and extract solution reclaims ethanol to without alcohol taste, is diluted with water to
Medicinal material ratio is 1: 5, filtering, and filtrate is through macroreticular resin (D101) successively with water (to colourless), 0.1%NaOH (4~5BV), 80%
Ethanol elution, collects 80% ethanol eluate, is concentrated to dryness, obtains Radix Ginseng Rubra total saponins；
(2) tuber of dwarf lilyturf, water is extracted 2 times, is merged extract solution, is recycled to medicinal material than 1: 5, is filtered, filtrate is through macroreticular resin
(D941) (2~4BV) is washed, collects efflux and water lotion, it is respectively 1.05-1.10,1.13-1.17, two to be concentrated into density
Secondary alcohol precipitation (80%, 85%), collects precipitation, and drying obtains tuber of dwarf lilyturf total starches；
(3) fruit of Chinese magnoliavine, is ground into coarse powder, and fruit of Chinese magnoliavine coarse powder obtains Fructus Schisandrae Chinensis volatile oil component and residue through supercritical extract,
Residue is extracted 2 times with 80% ethanol, merges extract solution, and extract solution filtering, filtrate merges, and it is 1: 5 to be concentrated into medicinal material ratio, filtering,
Filtrate successively with water (to colourless), 95% ethanol elution, collects 95% ethanol eluate, eluent is dense through macroreticular resin (AB-8)
It is reduced to dry, obtains fruit of Chinese magnoliavine lignanoid.
Embodiment 7
Active component Radix Ginseng Rubra total saponins, tuber of dwarf lilyturf total starches, fruit of Chinese magnoliavine lignanoid, other preparation sides of fruit of Chinese magnoliavine total volatile oil
Method：
(1) red ginseng, 20% ethanol is extracted 1 time, merges extract solution, and extract solution reclaims ethanol to without alcohol taste, is diluted with water to
Medicinal material ratio is 1: 2, filtering, and filtrate is through macroreticular resin (D101) successively with water (to colourless), 0.1%NaOH (4~5BV), 20%
Ethanol elution, collects eluent, is concentrated to dryness, obtains Radix Ginseng Rubra total saponins；
(2) tuber of dwarf lilyturf, water is extracted 1 time, is merged extract solution, is recycled to medicinal material than 1: 2, is filtered, filtrate is through macroreticular resin
(D941) (2~4BV) is washed, collects efflux and water lotion, it is respectively 1.05~1.10,1.13~1.17 to be concentrated into density,
Alcohol precipitation (60%, 65%), collects precipitation twice, and drying obtains tuber of dwarf lilyturf total starches；
(3) fruit of Chinese magnoliavine, is ground into coarse powder, and fruit of Chinese magnoliavine coarse powder obtains Fructus Schisandrae Chinensis volatile oil component and residue through supercritical extract,
Residue is extracted 1 time with 20% ethanol, merges extract solution, and extract solution filtering, filtrate merges, and it is 1: 2 to be concentrated into medicinal material ratio, filtering,
Filtrate uses water (to colourless), 30% ethanol elution through macroreticular resin (AB-8) successively, and eluent is concentrated to dryness, and obtains the wooden fat of the fruit of Chinese magnoliavine
Element.
Embodiment 8
Active component Radix Ginseng Rubra total saponins, tuber of dwarf lilyturf total starches, fruit of Chinese magnoliavine lignanoid, other preparation sides of fruit of Chinese magnoliavine total volatile oil
Method：
(1) red ginseng, 95% ethanol is extracted 5 times, merges extract solution, and extract solution reclaims ethanol to without alcohol taste, is diluted with water to
Medicinal material ratio is 1: 10, filtering, and filtrate is through macroreticular resin (D101) successively with water (to colourless), 10%NaOH (4~5BV), 95%
Ethanol elution, collects eluent, is concentrated to dryness, obtains Radix Ginseng Rubra total saponins；
(2) tuber of dwarf lilyturf, water is extracted 5 times, is merged extract solution, is recycled to medicinal material than 1: 10, is filtered, filtrate is through macroreticular resin
(D941) (2~4BV) is washed, collects efflux and water lotion, it is respectively 1.05~1.10,1.13~1.17 to be concentrated into density,
Alcohol precipitation (80%, 85%), collects precipitation twice, and drying obtains tuber of dwarf lilyturf total starches；
(3) fruit of Chinese magnoliavine, is ground into coarse powder, and fruit of Chinese magnoliavine coarse powder obtains Fructus Schisandrae Chinensis volatile oil component and residue through supercritical extract,
Residue is extracted 5 times with 95% ethanol, merges extract solution, and extract solution filtering, filtrate merges, and it is 1: 10 to be concentrated into medicinal material ratio, filtering,
Filtrate uses water (to colourless), 95% ethanol elution through macroreticular resin (AB-8) successively, and eluent is concentrated to dryness, and obtains the wooden fat of the fruit of Chinese magnoliavine
Element.
Embodiment 9
Active component Radix Ginseng Rubra total saponins, tuber of dwarf lilyturf total starches, fruit of Chinese magnoliavine lignanoid, other preparation sides of fruit of Chinese magnoliavine total volatile oil
Method：
(1) red ginseng, 50% ethanol is extracted 3 times, merges extract solution, and extract solution reclaims ethanol to without alcohol taste, is diluted with water to
Medicinal material ratio is 1: 5, filtering, and filtrate is through macroreticular resin (D101) successively with water (to colourless), 5%NaOH (4~5BV), 50% second
Alcohol is eluted, and is collected eluent, is concentrated to dryness, obtains Radix Ginseng Rubra total saponins；
(2) tuber of dwarf lilyturf, water is extracted 3 times, is merged extract solution, is recycled to medicinal material than 1: 5, is filtered, filtrate is through macroreticular resin
(D941) (2~4BV) is washed, collects efflux and water lotion, it is respectively 1.05~1.10,1.13~1.17 to be concentrated into density,
Alcohol precipitation (70%, 75%), collects precipitation twice, and drying obtains tuber of dwarf lilyturf total starches；
(3) fruit of Chinese magnoliavine, is ground into coarse powder, and fruit of Chinese magnoliavine coarse powder obtains Fructus Schisandrae Chinensis volatile oil component and residue through supercritical extract,
Residue is extracted 3 times with 50% ethanol, merges extract solution, and extract solution filtering, filtrate merges, and it is 1: 5 to be concentrated into medicinal material ratio, filtering,
Filtrate uses water (to colourless), 50% ethanol elution through macroreticular resin (AB-8) successively, and eluent is concentrated to dryness, and obtains the wooden fat of the fruit of Chinese magnoliavine
Element.
Embodiment 10
Active component Radix Ginseng Rubra total saponins, tuber of dwarf lilyturf total starches, fruit of Chinese magnoliavine lignanoid, other preparation sides of fruit of Chinese magnoliavine total volatile oil
Method：
(1) red ginseng, 95% ethanol is extracted 1 time, merges extract solution, and extract solution reclaims ethanol to without alcohol taste, is diluted with water to
Medicinal material ratio is 1: 2, filtering, and filtrate is through macroreticular resin (D101) successively with water (to colourless), 10%NaOH (4~5BV), 95% second
Alcohol is eluted, and is collected eluent, is concentrated to dryness, obtains Radix Ginseng Rubra total saponins；
(2) tuber of dwarf lilyturf, water is extracted 1 time, is merged extract solution, is recycled to medicinal material than 1: 2, is filtered, filtrate is through macroreticular resin
(D941) (2~4BV) is washed, collects efflux and water lotion, it is respectively 1.05~1.10,1.13~1.17 to be concentrated into density,
Alcohol precipitation (80%, 85%), collects precipitation twice, and drying obtains tuber of dwarf lilyturf total starches；
(3) fruit of Chinese magnoliavine, is ground into coarse powder, and fruit of Chinese magnoliavine coarse powder obtains Fructus Schisandrae Chinensis volatile oil component and residue through supercritical extract,
Residue is extracted 1 time with 95% ethanol, merges extract solution, and extract solution filtering, filtrate merges, and it is 1: 10 to be concentrated into medicinal material ratio, filtering,
Filtrate uses water (to colourless), 95% ethanol elution through macroreticular resin (AB-8) successively, and eluent is concentrated to dryness, and obtains the wooden fat of the fruit of Chinese magnoliavine
Element.
Claims (11)
1. a kind of pharmaceutical composition containing Shengmai Yin active ingredient, the active ingredient of said composition by：Radix Ginseng Rubra total saponins 10 ~ 80
Parts by weight, the parts by weight of tuber of dwarf lilyturf total starches 100 ~ 800, the parts by weight of fruit of Chinese magnoliavine lignanoid 0.375 ~ 12, fruit of Chinese magnoliavine total volatile oil 0.2 ~
1.6 parts by weight are constituted.
2. a kind of pharmaceutical composition as claimed in claim 1, the active ingredient of said composition by：The weight of Radix Ginseng Rubra total saponins 20 ~ 80
Amount part, the parts by weight of tuber of dwarf lilyturf total starches 200 ~ 800, the parts by weight of fruit of Chinese magnoliavine lignanoid 0.375 ~ 1.5, fruit of Chinese magnoliavine total volatile oil 0.4 ~
1.6 parts by weight are constituted.
3. a kind of pharmaceutical composition as claimed in claim 1, the active ingredient of said composition by：The weight of Radix Ginseng Rubra total saponins 80
Part, the parts by weight of tuber of dwarf lilyturf total starches 800, the parts by weight of fruit of Chinese magnoliavine lignanoid 1.5, the parts by weight of fruit of Chinese magnoliavine total volatile oil 1.6 composition.
4. a kind of pharmaceutical composition as claimed in claim 1, the active ingredient of said composition by：The weight of Radix Ginseng Rubra total saponins 40
Part, the parts by weight of tuber of dwarf lilyturf total starches 400, the parts by weight of fruit of Chinese magnoliavine lignanoid 0.75, the parts by weight of fruit of Chinese magnoliavine total volatile oil 0.8 composition.
5. a kind of pharmaceutical composition as claimed in claim 1, the active ingredient of said composition by：The weight of Radix Ginseng Rubra total saponins 20
Part, the parts by weight of tuber of dwarf lilyturf total starches 200, the parts by weight of fruit of Chinese magnoliavine lignanoid 0.375, the parts by weight of fruit of Chinese magnoliavine total volatile oil 0.4 composition.
6. a kind of pharmaceutical composition as claimed in claim 1, said composition contains pharmaceutically acceptable carrier.
7. a kind of pharmaceutical composition as claimed in claim 1, said composition is the medicine of gastrointestinal administration or parenteral administration
Thing preparation.
8. a kind of preparation method of pharmaceutical composition as claimed in claim 1, it is characterised in that by mixing the total soap of red ginseng
Glycosides, tuber of dwarf lilyturf total starches, fruit of Chinese magnoliavine lignanoid, fruit of Chinese magnoliavine total volatile oil is prepared with galenic pharmacy routine techniques.
9. a kind of preparation method as claimed in claim 8, wherein the Radix Ginseng Rubra total saponins, tuber of dwarf lilyturf total starches, fruit of Chinese magnoliavine lignanoid, five
Taste total volatile oil is prepared in accordance with the following methods respectively：
(1) red ginseng, 20 ~ 95% ethanol are extracted 1 ~ 5 time, merge extract solution, and extract solution reclaims ethanol to without alcohol taste, is diluted with water to
Medicinal material ratio is 1：2~1：10, filtering, filtrate uses water, 4 ~ 5BV 0.1 ~ 10% NaOH, 20 ~ 95% ethanol successively through macroreticular resin
Elution, collects eluent, is concentrated to dryness, obtains Radix Ginseng Rubra total saponins；
(2) tuber of dwarf lilyturf, water is extracted 1 ~ 5 time, is merged extract solution, is recycled to medicinal material and compares 1：2~1：10, filtering, filtrate is used through macroreticular resin
2 ~ 4BV washing, collects efflux and water lotion, it is respectively 1.05 ~ 1.10,1.13 ~ 1.17 to be concentrated into density, twice alcohol precipitation,
Concentration is respectively 60 ~ 80%, 65 ~ 85%, collects precipitation, and drying obtains tuber of dwarf lilyturf total starches；
(3) fruit of Chinese magnoliavine, is ground into coarse powder, and fruit of Chinese magnoliavine coarse powder obtains Fructus Schisandrae Chinensis volatile oil component and residue, residue through supercritical extract
Extracted 1 ~ 5 time with 20 ~ 95% ethanol, merge extract solution, extract solution filtering, filtrate merges, and it is 1 to be concentrated into medicinal material ratio：2~1：10,
Filtering, filtrate uses water, 30 ~ 95% ethanol elutions successively through macroreticular resin, and eluent is concentrated to dryness, and obtains fruit of Chinese magnoliavine lignanoid.
10. a kind of preparation method as claimed in claim 8, wherein the Radix Ginseng Rubra total saponins, tuber of dwarf lilyturf total starches, fruit of Chinese magnoliavine lignanoid,
Fruit of Chinese magnoliavine total volatile oil is prepared in accordance with the following methods respectively：
(1) red ginseng, 80% ethanol is extracted 2 times, merges extract solution, and extract solution reclaims ethanol to without alcohol taste, is diluted with water to medicinal material ratio
For 1：5, filtering, filtrate uses water, 4 ~ 5BV 0.1% NaOH, 80% ethanol elution successively through macroreticular resin, collects eluent, dense
It is reduced to dry, obtains Radix Ginseng Rubra total saponins；
(2) tuber of dwarf lilyturf, water is extracted 2 times, is merged extract solution, is recycled to medicinal material and compares 1:5, filtering, filtrate is through macroreticular resin with 2 ~ 4BV's
Washing, collects efflux and water lotion, and it is respectively 1.05-1.10,1.13-1.17 to be concentrated into density, twice alcohol precipitation, concentration difference
For 80%, 85%, precipitation is collected, drying obtains tuber of dwarf lilyturf total starches；
(3) fruit of Chinese magnoliavine, is ground into coarse powder, and fruit of Chinese magnoliavine coarse powder obtains Fructus Schisandrae Chinensis volatile oil component and residue, residue through supercritical extract
Extracted 2 times with 80% ethanol, merge extract solution, extract solution filtering, filtrate merges, and it is 1 to be concentrated into medicinal material ratio：5, filtering, filtrate warp
Macroreticular resin uses water, 95% ethanol elution successively, and eluent is concentrated to dryness, and obtains fruit of Chinese magnoliavine lignanoid.
11. application of the pharmaceutical composition on the medicine for preparing treatment chronic heart failure described in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210123804.1A CN103372138B (en) | 2012-04-25 | 2012-04-25 | A kind of pharmaceutical composition containing Shengmai Yin active ingredient and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210123804.1A CN103372138B (en) | 2012-04-25 | 2012-04-25 | A kind of pharmaceutical composition containing Shengmai Yin active ingredient and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103372138A CN103372138A (en) | 2013-10-30 |
| CN103372138B true CN103372138B (en) | 2017-07-28 |
Family
ID=49458383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210123804.1A Active CN103372138B (en) | 2012-04-25 | 2012-04-25 | A kind of pharmaceutical composition containing Shengmai Yin active ingredient and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103372138B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940595A (en) * | 2015-07-17 | 2015-09-30 | 中国中医科学院中药研究所 | Effect of pulse-activating decoction in prevention and treatment of myocardial ischemic disease trigged by fog and haze |
| CN107854609A (en) * | 2017-12-19 | 2018-03-30 | 西北大学 | Red ginseng, the tuber of dwarf lilyturf, fruit of Chinese magnoliavine composition are used for the purposes for preparing the medicine for the treatment of depression |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813900A (en) * | 2005-02-05 | 2006-08-09 | 苏州市思源医药科技有限公司 | Kadsura longipedunculata lignin extract and its preparing method and use |
| CN101744997A (en) * | 2008-12-05 | 2010-06-23 | 天津天士力之骄药业有限公司 | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007006208A1 (en) * | 2005-07-14 | 2007-01-18 | National Institute Of Pharmaceutical R & D Co., Ltd. | Medicinal composition containing ginseng secondary glycosides, its preparation method and application |
-
2012
- 2012-04-25 CN CN201210123804.1A patent/CN103372138B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813900A (en) * | 2005-02-05 | 2006-08-09 | 苏州市思源医药科技有限公司 | Kadsura longipedunculata lignin extract and its preparing method and use |
| CN101744997A (en) * | 2008-12-05 | 2010-06-23 | 天津天士力之骄药业有限公司 | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof |
Non-Patent Citations (4)
| Title |
|---|
| 生脉散治疗心力衰竭研究近况;瞿媛等;《山东中医杂志》;20090430;第28卷(第4期);第277-279页 * |
| 生脉胶囊质量标准研究;张正锋等;《中国药业》;20101231;第19卷(第16期);第28-30页 * |
| 益气养阴和解毒活血对大鼠急性心梗后早期心室重构和心肌TOLL样受体表达的影响;徐伟等;《深圳中西医结合杂志》;20091031;第19卷(第5期);第268-273页，尤其是第271页右栏倒数第2段 * |
| 益气养阴和解毒活血法对大鼠急性心梗后早期心室重构和心肌TOLL样受体表达的影响;徐伟等;《深圳中西医结合杂志》;20091031;第19卷(第5期);第268-273页，尤其是第271页右栏倒数第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103372138A (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102772748B (en) | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof | |
| CN103961521A (en) | Traditional Chinese medicine composition for treating aplastic anemia and preparation method | |
| CN103301413A (en) | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia | |
| CN103933346A (en) | Blood-glucose-reducing composition and preparation method thereof | |
| CN103372138B (en) | A kind of pharmaceutical composition containing Shengmai Yin active ingredient and preparation method thereof | |
| CN103463409B (en) | Traditional Chinese medicine formula for treating heart qi deficiency | |
| CN103070943A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine | |
| CN101677989A (en) | A pharmaceutical composition for preventing and treating ischemic stroke and its preparation method | |
| CN105833219A (en) | Traditional Chinese medicine composition for treating premature beat | |
| CN114712458B (en) | Pharmaceutical composition for treating vascular aging of hypertension and preparation method and application thereof | |
| CN110292607B (en) | Traditional Chinese medicine composition and preparation method for treating hypertension complicated with left ventricular hypertrophy | |
| CN103372139B (en) | Medicine composition containing effective components of pulse-activating decoction | |
| CN104606570A (en) | Consumptive thirst tea substitute drink suitable for diabetes patients and preparation method of consumptive thirst tea substitute drink | |
| CN104096073A (en) | Traditional Chinese medicine composition for treating male infertility and preparation method for same | |
| CN104256618A (en) | Food, health care product or medicine composition with blood sugar reduction function | |
| CN109223867A (en) | The relieving cough and reducing sputum Chinese medicine composition and its preparation method and application relievingd asthma | |
| CN103599211B (en) | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof | |
| CN103169856B (en) | A kind of Chinese medicine composition containing Rhizoma Coptidis | |
| CN109419914A (en) | The new application of Chinese medicine composition | |
| CN101152247A (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN101259180A (en) | A kind of ginseng tongue composition and its preparation method | |
| CN101167784A (en) | Medicinal composition for cardiovascular and cerebrovascular diseases | |
| CN105770479A (en) | Traditional Chinese medicinal composition for treating uveitis and preparation method thereof | |
| CN105012731A (en) | Traditional Chinese medicine for preventing postpartum hemorrhage and preparation method of traditional Chinese medicine | |
| CN104096212A (en) | Traditional Chinese medicine application for treating myocardial infarction and application for same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee before: Tasly Pharmaceutical Group Co., Ltd. |